Table 1 Efficacy results by group and dose level (per protocol analysis)
2× daily | 4× daily | Group comparison | |
|---|---|---|---|
Level1 MB 36 mg/kg | |||
- ETF/N | 1.6%, 1/62 | 3.0%, 2/66 | p = 0.5923 (1) |
- LCF14/N | 8.1%, 5/62 | 3.0%, 2/66 | p = 0.2047 (1) |
- TF14/N | 9.7%, 6/62 | 6.1%, 4/66 | p = 0.4452 (1) |
- LPF14/N | 24.2%, 15/62 | 22.7%, 15/66 | p = 0.8449 (1) |
Level2 MB 54 mg/kg | |||
- ETF/N | 3.1%, 2/64 | 6.9%, 5/73 | p = 0.3140 (1) |
- LCF14/N | 4.7%, 3/64 | 11.0%, 8/73 | p = 0.1688 (1) |
- TF14/N | 7.8%, 5/64 | 17.8%, 13/73 | p = 0.0783 (1) |
- LPF14/N | 35.9%, 23/64 | 17.8%, 13/73 | p = 0.0159 (1) |
Level3 MB 72 mg/kg | |||
- ETF/N | 0.0%, 0/47 | 0.0%, 0/52 | - |
- LCF14/N | 10.6%, 5/47 | 9.6%, 5/52 | p = 0.8661 (1) |
- TF14/N | 10.6%, 5/47 | 9.6%, 5/52 | p = 0.8661 (1) |
- LPF14/N | 21.3%, 10/47 | 19.2%, 10/52 | p = 0.8002 (1) |
Level comparison | |||
- p-value (ETF) | 0.3266 (2) | 0.0595 (2) | 0.7290 (3), 0.0960 (4), 0.9930 (5) |
- p-value (LCF14) | 0.4824 (2) | 0.1492 (2) | 0.3168 (3), 0.2613 (4), 0.1722 (5) |
- p-value (LF14) | 0.8684 (2) | 0.0838 (2) | 0.2944 (3), 0.2634 (4), 0.1984 (5) |
- p-value (LPF14) | 0.1764 (2) | 0.7631 (2) | 0.1155 (3), 0.4045 (4), 0.2486 (5) |